Novo Nordisk (CPSE:NOVO B) Wins Dutch Injunction Over Compounded Semaglutide Spray
Novo Nordisk has successfully obtained a Dutch court injunction to block the production and distribution of an unapproved compounded semaglutide nasal spray. This legal victory strengthens the company's patent protections for its popular GLP-1 diabetes and obesity treatments.
Why it matters
The ruling sets a legal precedent for how pharmaceutical companies can defend their intellectual property against compounded alternatives in the growing weight-loss drug market.
Novo Nordisk (CPSE:NOVO B) Wins Dutch Injunction Over Compounded Semaglutide Spray Bailey Pemberton Sat, August 8, 2026 at 7:10 PM EDT 2 min read NVO +2.81% NVO +2.81% Explore stocks on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE.
Novo Nordisk (CPSE:NOVO B) secured a Dutch court injunction against Ceban Ziekenhuisfarmacie over an unapproved compounded semaglutide nasal spray.
The ruling blocks production and distribution of the compounded nasal spray in the Netherlands for infringing Novo Nordisk's semaglutide patent.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in